Pfizer’s attempt to buy AstraZeneca over the last 6 weeks has been a total failure. As the saga progressed, the real question in my mind shifted from all the political wrangling and negotiation to why Pfizer seemed …
Continue readingPFE
Here is a list of the some of the large options flow that caught our eye in an otherwise quiet day on a volume basis: 1. GM – had one of its worst days in …
Continue reading
In a day that saw generally risk off activity, there was some interesting options activity that suggested some market participants were closing bearish bets or monetizing hedges in ETFs and Index options that dominated most …
Continue reading
Today is the last major options expiry of 2013. Options traders, including ourselves, will mostly be left with options positions in 2014 after today. In preparation for the start of the new year, I wanted …
Continue reading
Abbvie has made several attempts in the past month to break above the $50 level, which it first touched in late October. The company had good Hepatitis C Treatment data in Phase III results released …
Continue reading
Abbott was one of the largest pharmaceutical companies in the world prior to its split in December 2012. The company spun off its proprietary pharmaceutical business (classic business of developing drugs for FDA approval and …
Continue reading
The third quarter went to the small caps. In fact, since the market’s May high, the Russell 2000 is up more than 6%, while the S&P 500 is essentially flat. But the biggest drag on …
Continue reading
Large Caps dominated options volumes. QCOM – Buyer of 10k of the Jan15 72.50 calls for 5.50, paired with selling 460,000 shares at $68.75. QCOM hit a new 10 year high this month. EBAY – EBAY made …
Continue reading
Continuing the trend of very low volumes on Mondays for the past 3 weeks. ATVI – Trader rolled the Sept 17 calls up to the Sept 19 calls, selling the call spread 55k times at 0.96. …
Continue reading
While there has been a rotation from defensives to cyclicals in the past month, health care is still the best performing sector in the U.S. market this year (up about 22% when measured by XLV). …
Continue reading